Literature DB >> 22198018

Thyrotropin-releasing hormone causes a tonic excitatory postsynaptic current and inhibits the phasic inspiratory inhibitory inputs in inspiratory-inhibited airway vagal preganglionic neurons.

L Hou1, X Zhou, Y Chen, D Qiu, L Zhu, J Wang.   

Abstract

The airway vagal preganglionic neurons (AVPNs) in the external formation of the nucleus ambiguus (eNA), which include the inspiratory-activated AVPNs (IA-AVPNs) and inspiratory-inhibited AVPNs (II-AVPNs), predominate in the control of the trachea and bronchia. The AVPNs receive particularly dense inputs from terminals containing thyrotropin-releasing hormone (TRH). TRH microinjection into the nucleus ambiguus (NA) caused constriction of the tracheal smooth muscles. However, it is unknown whether TRH affects all subtypes of the AVPNs in the eNA, and as a result affects the control of all types of target tissues in the airway (smooth muscles, submucosal glands, and blood vessels). It is also unknown how TRH affects the AVPNs at neuronal and synaptic levels. In this study, the AVPNs in the eNA were retrogradely labeled from the extrathoracic trachea, the II-AVPNs were identified in rhythmically firing brainstem slices, and the effects of TRH were examined using patch-clamp. TRH (100 nmol L(-1)) enhanced both the rhythm and the intensity of the hypoglossal bursts, and caused a tonic excitatory inward current in the II-AVPNs at a holding voltage of -80 mV. The frequency of the spontaneous excitatory postsynaptic currents (EPSCs) in the II-AVPNs, which showed no respiratory-related change in a respiratory cycle, was not significantly changed by TRH. At a holding voltage of -50 mV, the II-AVPNs showed both spontaneous and phasic inspiratory (outward) inhibitory postsynaptic currents (IPSCs). TRH had no effect on the spontaneous IPSCs but significantly attenuated the phasic inspiratory outward currents, in both the amplitude and area. After focal application of strychnine, an antagonist of glycine receptors, to the II-AVPNs, the spontaneous IPSCs were extremely scarce and the phasic inspiratory inhibitory currents were abolished; and further application of TRH had no effect on these currents. Under current clamp configuration, TRH caused a depolarization and increased the firing rate of the II-AVPNs during inspiratory intervals. These results demonstrate that TRH affects the II-AVPNs both postsynaptically via a direct excitatory current and presynaptically via attenuation of the phasic glycinergic synaptic inputs.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198018     DOI: 10.1016/j.neuroscience.2011.12.003

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  4 in total

Review 1.  Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?

Authors:  Marieke Hyke Algera; Joseph F Cotten; Monique van Velzen; Marieke Niesters; Martijn Boon; Daniel S Shoham; Kaye E Dandrea; Rutger van der Schrier; Albert Dahan
Journal:  Pharmacol Res Perspect       Date:  2022-06

2.  Arginine Vasopressin Alters Both Spontaneous and Phase-Locked Synaptic Inputs to Airway Vagal Preganglionic Neuron via Activation of V1a Receptor: Insights into Stress-Related Airway Vagal Excitation.

Authors:  Xianxia Yan; Xingxin Chen; Yuhong Guo; Ding He; Yonghua Chen; Chunmei Xia; Jijiang Wang
Journal:  Front Cell Neurosci       Date:  2017-02-02       Impact factor: 5.505

3.  Inspiratory-Activated Airway Vagal Preganglionic Neurones Excited by Thyrotropin-Releasing Hormone via Multiple Mechanisms in Neonatal Rats.

Authors:  Lili Hou; Min Zhang; Xingyi Zhang; Zhenwei Liu; Pengyu Zhang; Dongying Qiu; Lei Zhu; Xin Zhou
Journal:  Front Physiol       Date:  2018-07-17       Impact factor: 4.566

Review 4.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.